Abstract
Background Mesenteric vein thrombosis (MVT) is a rare, often lethal, entity that accounts for approximately 10-15% of all cases of mesenteric ischemia [1,2]. Current indications for surgery in patients with acute MVT include signs of peritonitis, bowel infarction and hemodynamic instability. In all other cases, long-lasting anticoagulation is the strategy of choice [3,4], patients with MVT have a fairly good prognosis and long-term outcomes once appropriate anticoagulation is achieved [4,5]. At variance with the slow onset of recanalization that takes place during anticoagulation, thrombolysis leads to a rapid re-opening of a vessel, with immediate tissue reperfusion [4].
Highlights
Mesenteric vein thrombosis (MVT) is a rare, often lethal, entity that accounts for approximately 10-15% of all cases of mesenteric ischemia [1,2]
In 16/18 patients (88.8%) following the percutaneous treatment, flow restoration in the thrombosed mesenteric vein was documented by direct portal venography (Fig. 1)
The 30-day mortality rate was similar in the two groups (p=0.998)
Summary
Mesenteric vein thrombosis (MVT) is a rare, often lethal, entity that accounts for approximately 10-15% of all cases of mesenteric ischemia [1,2]. Current indications for surgery in patients with acute MVT include signs of peritonitis, bowel infarction and hemodynamic instability. Long-lasting anticoagulation is the strategy of choice [3,4], patients with MVT have a fairly good prognosis and long-term outcomes once appropriate anticoagulation is achieved [4,5]. At variance with the slow onset of recanalization that takes place during anticoagulation, thrombolysis leads to a rapid re-opening of a vessel, with immediate tissue reperfusion [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
